GGrantIndex
← Leaderboards

Shaji Kunnathu Kumar

Mayo Clinic Rochester

Google Scholar ↗PubMed ↗ORCID ↗
$7,127,192
Attributed
$12,581,295
Total exposure
6
Grants
2
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2.3M · FY2012–25
$2.5M$1.9M$1.3M$625K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$13,892,863 · 7

By mechanism

R01$7,139,559 · 3
U01$2,826,486 · 1
P30$2,300,788 · 1
U54$1,626,030 · 2

Top collaborators

Most similar at Mayo Clinic Rochester

Same institution · by research overlap

Others in their field

Top investigators on “Multiple Myeloma”

Research focus

Multiple MyelomaMalignant NeoplasmsMorbidity - Disease RatePlasma CellsFirst Degree RelativeMonoclonal Gammopathy Of Uncertain SignificanceBaseCohortPersonsHigh RiskEtiologyRisk FactorsSamplingScreeningIncidencePredispositionCessation Of LifePrevalenceGenomicsMarrowPopulation BasedClinicResponseAfrican American

Grant awards (32)

Impact of Genetic susceptibility along the continuum from MGUS to MM$659,222
U01 · FY2025 · CA
Impact of Genetic susceptibility along the continuum from MGUS to MM$621,962
U01 · FY2024 · CA
Onset and biomarkers for progression of monoclonal gammopathies$78,948
R01 · FY2024 · CA
Impact of Genetic susceptibility along the continuum from MGUS to MM$650,438
U01 · FY2023 · CA
Onset and biomarkers for progression of monoclonal gammopathies$414,033
R01 · FY2023 · CA
Impact of Genetic susceptibility along the continuum from MGUS to MM$694,881
U01 · FY2022 · CA
Clinical Protocol and Data Management$558,028
P30 · FY2022 · CA · contact PI
Onset and biomarkers for progression of monoclonal gammopathies$434,502
R01 · FY2022 · CA
Impact of Genetic susceptibility along the continuum from MGUS to MM (Supplement)$199,983
U01 · FY2022 · CA
Clinical Protocol and Data Management$557,904
P30 · FY2021 · CA · contact PI
Project 2 - IMiD Resistance in Patients and Humanized Mice with Multiple Myeloma$314,462
U54 · FY2021 · CA · contact PI
Onset and biomarkers for progression of monoclonal gammopathies$94,779
R01 · FY2021 · CA
Clinical Protocol and Data Management$560,347
P30 · FY2020 · CA · contact PI
Onset and biomarkers for progression of monoclonal gammopathies$217,458
R01 · FY2020 · CA
Overcoming Drug Resistance in Multiple Myeloma$1,311,568
U54 · FY2019 · CA
Clinical Protocol and Data Management$624,509
P30 · FY2019 · CA · contact PI
Onset and biomarkers for progression of monoclonal gammopathies$377,625
R01 · FY2019 · CA
The Role of Cereblon Pathways in Myeloma$446,267
R01 · FY2018 · CA
Prevalence and Progression of Monoclonal Gammopathies$321,975
R01 · FY2018 · CA
The Role of Cereblon Pathways in Myeloma$446,267
R01 · FY2017 · CA
Prevalence and Progression of Monoclonal Gammopathies$321,975
R01 · FY2017 · CA
The Role of Cereblon Pathways in Myeloma$446,267
R01 · FY2016 · CA
Onset and biomarkers for progression of monoclonal gammopathies$329,925
R01 · FY2016 · CA
Prevalence and Progression of Monoclonal Gammopathies$321,975
R01 · FY2016 · CA
The Role of Cereblon Pathways in Myeloma$459,038
R01 · FY2015 · CA
Onset and biomarkers for progression of monoclonal gammopathies$329,925
R01 · FY2015 · CA
Prevalence and Progression of Monoclonal Gammopathies$321,975
R01 · FY2015 · CA
The Role of Cereblon Pathways in Myeloma$494,568
R01 · FY2014 · CA
Prevalence and Progression of Monoclonal Gammopathies$321,975
R01 · FY2014 · CA
Onset and biomarkers for progression of monoclonal gammopathies$320,027
R01 · FY2014 · CA
Onset and biomarkers for progression of monoclonal gammopathies$310,130
R01 · FY2013 · CA
Onset and biomarkers for progression of monoclonal gammopathies$329,925
R01 · FY2012 · CA